According to a recent LinkedIn post from Circular Genomics, CEO Paul Sargeant is featured on the Healthcare Happenings podcast discussing how circular RNA may open new avenues in brain health diagnostics. The post indicates the discussion covers the underlying science of circular RNA and Circular Genomics’ expanding product pipeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also notes the launch of an Alzheimer’s research-use-only assay and a systems-level approach that looks beyond the traditional amyloid-tau framework. The content further suggests the company is preparing for future commercialization, which could signal a move toward revenue-generating diagnostic offerings and strengthen its positioning in the neurodegenerative disease diagnostics market.